Form Type and Filing Date: Current Report on Form 8-K filed by Johnson & Johnson on July 29, 2026, reporting events as of the same date Item 5.02 - Regulation FD Disclosure: The filing indicates disclosure of information under Regulation FD (Fair Disclosure), though the specific details of the disclosure are not fully visible in the provided document excerpt Item 9.01 - Financial Statements and…

Our analysis rates this filing CAUTIOUS. The elevated concern level (6.8/10) reflects a material near-term earnings headwind from recent strategic transactions, particularly the Firefly Bio acquisition. The 5.5% EPS guidance reduction and 150 basis point margin compression represent quantified,…

Concern level: HIGH (6.8/10). Key factors: One high-severity risk identified (Significant EPS Dilution, severity 7/10) with material near-term earnings impact of $0.64 per share (5.5% reduction in 2026 EPS guidance midpoint); Overall risk trend is INCREASING with risk score of 6.8/10, indicating deteriorating conditions; Guidance cut: EPS growth midpoint reduced from 7.3% to 1.4% (580 basis point…

Notable risk changes: Firefly Bio acquisition completed with $0.46 EPS headwind in 2026, representing material near-term earnings dilution and integration execution risk in gene therapy sector; Full-year 2026 EPS guidance reduced by $0.64 (5.5% reduction), with adjusted operational EPS midpoint declining from $11.58 to $10.94, signaling significant margin compression and integration costs; Operating margin guidance…

The model predicts JNJ will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.